Programmed Cell Death (PD) Inhibitors Dominate Head and Neck Cancer Therapeutics Market with a share of 42.1% in 2024
A new report from Industry Experts Inc, on " Head and Neck Cancer Therapeutics ," is introduced. According to this global market research report, the global market for Head and Neck Cancer Therapeutics is estimated at US$1.7 billion in 2024 and is anticipated to post a CAGR of 9.4% during the 2024-2030 analysis period and stand at a projected US$3 billion by 2030. The head and neck cancer market is primarily driven by increased research and development, which leads to the approval of new drugs, particularly for immunotherapy, targeted therapy, and chemotherapy. Healthcare providers are developing effective treatment options for several types of head and neck cancers, as evidenced by FDA approvals for drugs like Cetuximab and Docetaxel. Market growth is also driven by the rising incidence of HPV infections and increased consumption of alcohol and tobacco, which contribute to the prevalence of head and neck cancers. Programmed Cell Death (PD) Inhibitors dominate ...